Nov 4, 7:56 PM ET
LifeStance reported third quarter 2026 revenue of $455.9 million, up 25%, and net income of $22.4 million, compared with $1.1 million a year earlier. The company raised its full-year 2026 guidance for revenue, Center Margin and Adjusted EBITDA, which points to stronger expected results for shareholders.
- Q3 2026 revenue $455.9 million, up 25% from $363.8 million; net income $22.4 million versus $1.1 million
- Adjusted EBITDA $68.4 million, up 70%; Center Margin $161.4 million, up 38%
- Full-year 2026 revenue guidance raised to $1.741 billion to $1.761 billion; Adjusted EBITDA to $242 million to $250 million
- Q4 2026 guidance: revenue $446 million to $466 million; Adjusted EBITDA $56 million to $64 million
Read the filing on SEC.gov ↗
Oct 16, 5:26 PM ET
LifeStance Health Group disclosed that director Teresa DeLuca, M.D., notified the board on October 14, 2026, of her resignation from the board and all of its committees, effective December 31, 2026. The company states the resignation is not the result of any disagreement with the company.
- Teresa DeLuca, M.D., resigns from the board of directors and all committees.
- Resignation notified to the board on October 14, 2026, effective December 31, 2026.
- Company states the resignation does not result from any disagreement with Dr. DeLuca.
- Filing does not name a replacement director or describe any financial effect.
Read the filing on SEC.gov ↗
Aug 5, 8:21 PM ET
LifeStance Health Group reported second-quarter 2026 revenue of $435.4 million, up 26%, and net income of $23.6 million, compared with a net loss of $3.8 million a year earlier. The company raised its full-year 2026 revenue, Center Margin and Adjusted EBITDA guidance and approved a new $100 million share repurchase program, which replaces its prior $100 million program from February 24, 2026.
- Q2 2026 revenue was $435.4 million, up 26% from $345.3 million; net income was $23.6 million versus a net loss of $3.8 million in Q2 2025.
- Adjusted EBITDA rose 94% to $66.0 million, or 15.2% of total revenue, compared with $34.0 million a year earlier.
- Full-year 2026 revenue guidance was raised to $1.685 billion to $1.725 billion, and Adjusted EBITDA guidance is $215 million to $235 million.
- The Board approved a $100 million share repurchase program on August 5, 2026, replacing the prior $100 million program approved February 24, 2026.
Read the filing on SEC.gov ↗
Jul 7, 4:27 PM ET
LifeStance Health Group said director Jeffrey Rhodes resigned from the board and all its committees effective immediately, and that the resignation was not due to any disagreement with the company. The board appointed Thurman Justice, Lori Goltermann and Safwan Shabab as directors to fill vacancies, a board change that is administrative in nature and carries no stated financial effect.
- Jeffrey Rhodes resigned from the board and all committees effective immediately, notified July 2, 2026
- Thurman Justice and Lori Goltermann appointed Class II directors, serving until the 2029 annual meeting
- Safwan Shabab appointed Class III director under a June 9, 2021 stockholder agreement, serving until the 2027 meeting
- Justice and Goltermann each received an initial award of 35,492 restricted stock units under the 2021 Equity Incentive Plan
Read the filing on SEC.gov ↗
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.